Table 2.

Selected Examples of Percentage of Reduction in the Prevalence of Genital Warts in the Vaccine Era Compared to the Prevaccine Era or in Vaccinated Females Compared With Contemporaneous Unvaccinated Females

Country	Supplementary Reference	Setting	% Reduction in Genital Warts
Australia (high vaccine uptake)	Chow 2015 [A27]	Melbourne Sexual Health Centre, Victoria, within 7 y after start of vaccine era	45% annually among females <21 y
	Smith 2016 [A43]	Hospital admissions for genital warts from national database, within 4 y after start of vaccine era	85%–87%, 10–19 y 62%–67%, 20–29 y
	Donovan 2011 [A28]	National surveillance, within 2 y after start of vaccine era	59%, 12–26 y
Denmark	Bollerup 2016 [A42]	National prescription inpatient/outpatient registries, within 5 y after start of vaccine era	43% annually, 12–15 y 55% annually, 16–17 y 39% annually, 18–19 y 21% annually, 20–21 y 12% annually, 22–25 y 6% annually, 26–29 y
Sweden	Herjweijer 2016 [A18]	National hospital admissions that included genital warts diagnosis code, within 4 y after start of vaccine era	82%, 10–16 y (3 vs 0 dose) 71%, 10–16 y (2 vs 0 dose) 69%, 10–16 y (1 vs 0 dose)
United States	Flagg 2013 [A30]	Claims data (inpatient/outpatient visits or pharmacy dispensing) from large claims database (Truven Health Analytics), within 3 y after start of vaccine era	No change, 10–14 y 38%, 15–19 y 13%, 20–24 y

More details regarding the impact and effectiveness of quadrivalent human papillomavirus vaccination on anogenital warts are provided in Supplementary Tables 4 and 5, respectively, in Supplementary Appendix II.

Reductions in genital warts occurred as early as 1 year after program implementation in Australia [A29] and Germany [A35].

Abbreviation: y, years.